Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,690 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ, Kang ES, Kim DJ, Kim SH, Ahn CW, Cha BS, Nam M, Chung CH, Lee KW, Nam CM, Lee HC. Kim HJ, et al. Among authors: chung ch. Clin Endocrinol (Oxf). 2007 Feb;66(2):282-9. doi: 10.1111/j.1365-2265.2006.02723.x. Clin Endocrinol (Oxf). 2007. PMID: 17224000 Clinical Trial.
Diabetes epidemics in Korea: reappraise nationwide survey of diabetes "diabetes in Korea 2007".
Task Force Team for Basic Statistical Study of Korean Diabetes Mellitus of Korean Diabetes Association; Park IeB, Kim J, Kim DJ, Chung CH, Oh JY, Park SW, Lee J, Choi KM, Min KW, Park JH, Son HS, Ahn CW, Kim H, Lee S, Lee IB, Choi I, Baik SH. Task Force Team for Basic Statistical Study of Korean Diabetes Mellitus of Korean Diabetes Association, et al. Among authors: chung ch. Diabetes Metab J. 2013 Aug;37(4):233-9. doi: 10.4093/dmj.2013.37.4.233. Diabetes Metab J. 2013. PMID: 23991400 Free PMC article.
Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension.
Jin SM, Park SW, Yoon KH, Min KW, Song KH, Park KS, Park JY, Park IB, Chung CH, Baik SH, Choi SH, Lee HW, Lee IK, Kim DM, Lee MK. Jin SM, et al. Among authors: chung ch. Diabetes Obes Metab. 2015 May;17(5):511-5. doi: 10.1111/dom.12429. Epub 2015 Jan 14. Diabetes Obes Metab. 2015. PMID: 25523633 Clinical Trial.
Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes.
Kim JH, Ahn JH, Kim SK, Lee DH, Kim HS, Shon HS, Jeon HJ, Kim TH, Cho YW, Kim JT, Han SM, Chung CH, Ryu OH, Lee JM, Lee SH, Kwon MJ, Kim TK, Namgoong IS, Kim ES, Jung IK, Moon SD, Han JH, Kim CH, Cho EH, Kim KY, Park HB, Lee KS, Lee SW, Lee SC, Kang CM, Jeon BS, Song MS, Yun SB, Chung HK, Seong JH, Jeong JY, Cha BY. Kim JH, et al. Among authors: chung hk, chung ch. J Diabetes Investig. 2015 Mar;6(2):219-26. doi: 10.1111/jdi.12261. Epub 2014 Aug 6. J Diabetes Investig. 2015. PMID: 25802730 Free PMC article.
A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes.
Yang HK, Min KW, Park SW, Chung CH, Park KS, Choi SH, Song KH, Kim DM, Lee MK, Sung YA, Baik SH, Kim IJ, Cha BS, Park JH, Ahn YB, Lee IK, Yoo SJ, Kim J, Park IeB, Park TS, Yoon KH. Yang HK, et al. Among authors: chung ch. Endocr J. 2015;62(5):449-62. doi: 10.1507/endocrj.EJ14-0544. Epub 2015 Mar 27. Endocr J. 2015. PMID: 25819061 Free article. Clinical Trial.
Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: A 24-week randomized non-inferiority trial.
Jin SM, Kim JH, Min KW, Lee JH, Ahn KJ, Park JH, Jang HC, Park SW, Lee KW, Won KC, Kim YI, Chung CH, Park TS, Lee JH, Lee MK. Jin SM, et al. Among authors: chung ch. J Diabetes. 2016 May;8(3):405-13. doi: 10.1111/1753-0407.12312. Epub 2015 Jun 29. J Diabetes. 2016. PMID: 25952532 Clinical Trial.
Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial.
Hong S, Park CY, Han KA, Chung CH, Ku BJ, Jang HC, Ahn CW, Lee MK, Moon MK, Son HS, Lee CB, Cho YW, Park SW. Hong S, et al. Among authors: chung ch. Diabetes Obes Metab. 2016 May;18(5):528-32. doi: 10.1111/dom.12631. Epub 2016 Mar 18. Diabetes Obes Metab. 2016. PMID: 26749529 Free PMC article. Clinical Trial.
1,690 results